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Background and PurposezzLow-density lipoprotein (LDL) particle size is considered to be 
one of the more important cardiovascular risk factors, and small LDL particles are known to 
have atherogenic potential. The aim of this study was to determine whether LDL particle size is 
associated with stroke severity and functional outcome in patients with atherothrombotic 
stroke.
MethodszzBetween January 2009 and May 2011, 248 patients with first-episode cerebral in-
farction who were admitted to our hospital within 7 days after symptom onset were prospec-
tively enrolled. LDL particle size was measured using the nondenaturing polyacrylamide gradi-
ent gel electrophoresis assay. Stroke severity was assessed by applying the National Institutes 
of Health Stroke Scale (NIHSS) at admission. Functional outcome was investigated at 3 
months after the index stroke using the modified Rankin Scale (mRS), and poor functional out-
come was defined as an mRS score of ≥3.
ResultszzThe LDL particle size in the 248 patients was 25.9±0.9 nm (mean±SD). LDL parti-
cle size was inversely correlated with the degree of cerebral artery stenosis (p=0.010). Multino-
mial multivariate logistic analysis revealed that after adjustment for age, sex, and variables with 
p<0.1 in univariate analysis, LDL particle size was independently and inversely associated with 
stroke severity (NIHSS score ≥5; reference, NIHSS score 0–2; odds ratio=0.38, p=0.028) and 
poor functional outcome (odds ratio=0.44, p=0.038).
ConclusionszzThe results of this study demonstrate that small LDL particles are independent-
ly correlated with stroke outcomes. LDL particle size is thus a potential biomarker for the prog-
nosis of atherothrombotic stroke. J Clin Neurol 2015;11(1):80-86
Key Wordszz low-density-lipoprotein particle size, lipoprotein, stroke severity,  
stroke outcome, atherosclerosis.
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Introduction
Hypercholesterolemia is closely associated with an increased 
risk of cardiovascular disease, including stroke, due to ath-
erosclerosis of blood vessels. Total cholesterol is made up of 
low-density lipoprotein (LDL), very-low-density lipoprotein, 
triglycerides (TG), and high-density lipoprotein (HDL). Ath-
erosclerosis is generally characterized by elevated plasma 
concentrations of TG or LDL and a decreased HDL concen-
tration.1 It has recently been shown that certain LDL, subclas-
sified according to particle size, are associated with athero-
sclerotic risk.2 LDL particle size is negatively associated with 
plasma TG levels, and the combination of small LDL particles 
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and increased plasma TG levels is considered to be the athero-
genic lipoprotein phenotype.3 Small LDL particles are more 
easily taken up by arterial tissue4 and are more susceptible to 
oxidative stress than are large LDL particles.5 Therefore, small 
LDL particles are considered to be associated with the pro-
gression of atherosclerosis6 and have been accepted by the 
National Cholesterol Education Program Adult Treatment Pan-
el III as one of the emerging cardiovascular risk factors.7
Clinical studies have emphasized the role of small LDL par-
ticles in the development of early atherosclerosis in meno-
pausal women,8 coronary heart disease including acute myo-
cardial infarction or coronary vasospasm,9-12 or peripheral 
arterial disease, regardless of the presence of diabetes melli-
tus.13 In stroke patients, small LDL particles are known to be 
associated with short-term mortality after acute ischemic 
stroke.14 However, there is as yet little information available 
on the relationship between LDL particle size and functional 
outcome after stroke, and including stroke severity. Therefore, 
in this study, the association between LDL particle and stroke 
severity and functional outcomes was investigated in patients 
with atherothrombotic stroke.
Methods
Subjects
Patients diagnosed with first-episode ischemic stroke and ad-
mitted to Ewha Womans University Mokdong Hospital with-
in 7 days after symptom onset were prospectively enrolled in 
this study between January 2009 and June 2011. Blood sam-
ples to be used for LDL particle analysis were obtained from 
all enrolled patients. Patient information was collected, and 
data were evaluated including past medical, medication, and 
familial history, brain imaging studies (CT and/or MRI), vas-
cular imaging studies (digital subtraction angiography, CT an-
giography, or MR angiography), chest X-ray, 12-lead electro-
cardiography, electrocardiography monitoring during a median 
time period of 3 days at a stroke intensive care unit, transtho-
racic echocardiography, and routine blood tests.15 Patients were 
excluded if they did not agree to provide blood samples for 
this study. Of the 427 initially eligible patients, 2 who received 
incomplete vascular imaging, 40 who had transient ischemic 
attacks with negative diffusion-weighted images, and 10 with 
rare causes of stroke, such as moyamoya disease, arterial dis-
section, or venous thrombosis, were excluded. Moreover, pa-
tients with a moderate or high risk of cardiac sources of embo-
lism (n=127) based on the Trial of Org 10172 in Acute Stroke 
Treatment classification system16 were excluded because acute 
cardioembolic occlusion of the artery could be mistaken for 
true arterial occlusion despite the absence of stenosis. Ulti-
mately, the data of 248 patients were analyzed in this study, 
which was approved by the Institutional Review Board of 
Ewha Womans University Mokdong Hospital.
Measurement of the degree of stenosis, stroke 
severity, and functional outcome
The degree of arterial stenosis was measured according to the 
method used in the North American Symptomatic Carotid 
Endarterectomy Trial17 for extracranial arteries, or based on the 
method used in the Warfarin-Aspirin Symptomatic Intracrani-
al Disease study18 for intracranial arteries. Vascular images 
were evaluated by two independent vascular neurologists (T.-
J.S. and H.-J.C.) who were blinded to the clinical information. 
Interobserver agreement on the presence of more than 50% 
stenosis and/or occlusion was excellent (κ=0.96), and cerebral 
artery stenosis was classified into three groups: ≥50% stenosis 
(one or more vessels with ≥50% stenosis), <50% stenosis (one 
or more vessels with <50% stenosis), and no atherosclerosis 
(i.e., no stenosis). The severity of neurologic deficits was de-
termined using the National Institutes of Health Stroke Scale 
(NIHSS) at admission.19 Functional outcomes were also as-
sessed using the modified Rankin Scale (mRS) at 3 months af-
ter the index stroke.
Measurement of LDL particle size and lipid 
profile
Blood samples were collected after fasting for >12 h for lipid 
profiling into plain, ethylenediaminetetraacetic acid-treated 
tubes within 24 hours after admission. The blood was centri-
fuged to separate the plasma or serum from the whole blood, 
and then stored at -70°C until analysis. Nondenaturing poly-
acrylamide gradient gel electrophoresis with lipid staining of 
the plasma was performed to determine the peak LDL parti-
cle diameter, as described elsewhere.20 Briefly, the whole 
plasma and the plasma fraction with a density of <1.063 kg/L 
(prepared by ultracentrifugation) were separated by electro-
phoresis using gradient gel (PAA 2/16, Pharmacia, Uppsala, 
Sweden). Gels were stained and then scanned with a scanning 
densitometer (Transidyne RFT, Ann Arbor, MI, USA), and 
the peak particle diameters of the main LDL subclasses were 
calculated from calibration curves using standards of known 
size. Serum concentrations of cholesterol, LDL, and HDL 
were measured with commercially available kits (Choong-
wae, Seoul, Korea) using enzymatic methods.21 The serum 
TG level was analyzed using a total glycerol test kit (Roche, 
Basel, Switzerland). All measurements were performed on an 
Hitachi 747 autoanalyzer (Hitachi, Tokyo, Japan). Plasma 
levels of lipoprotein (a) were measured using an enzyme-
linked immunosorbent assay, according to the manufactur-
er’s instructions (R&D Systems, Minneapolis, MN, USA). 
Each sample was measured in duplicate and the mean of the 
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two values was used in the analysis.21
Risk factors
Hypertension was defined as a resting systolic blood pressure 
of ≥140 mm Hg or a diastolic blood pressure of ≥90 mm Hg 
on repeated measurements, or receiving treatment with antihy-
pertensive medications. Diabetes mellitus was diagnosed if the 
patient had a fasting blood glucose level of ≥7.0 mmol/L or 
was being treated with oral hypoglycemic agents or insulin. 
Hyperlipidemia was diagnosed if the patient had an LDL-cho-
lesterol level of ≥4.1 mmol/L, a total cholesterol level of ≥6.2 
mmol/L, or if the patient was being treated with lipid-lowering 
agents after being diagnosed with hyperlipidemia. Patients 
were defined as smokers if they were current smokers or if they 
had stopped smoking within 1 year before the stroke event. 
The presence of coronary heart disease was determined when 
a patient had a history of unstable angina, myocardial infarc-
tion, or angiographically confirmed coronary artery disease. A 
positive family history was considered as a history of coronary 
heart disease or stroke, regardless of their type (ischemic or 
hemorrhagic). If the cause of disease was unknown in a family 
member, the family history in the subject was defined as neg-
ative.
Statistical analysis
Statistical analyses were performed using the Windows SPSS 
software package (version 18.0, SPSS Inc., Chicago, IL, USA). 
Continuous variables are expressed as mean±SD values, or as 
medians and interquartile ranges (IQRs). Categorical variables 
are expressed as frequencies and percentages. Independent t-
test, Mann-Whitney U test, one-way analysis of variance with 
Bonferroni corrected post-hoc analyses, and the Kruskal-Wal-
lis test were used to compare continuous values. Categorical 
variables were compared using the chi-square test or Fisher’s 
exact test. Since the continuous and ordinal variables of this 
study did not exhibit normality according to the Kolmogorov-
Smirnov test (except HDL and total cholesterol), even though 
logarithmically transformed, NIHSS score was trichotomized 
based on their tertiles for uni- and multivariate analyses. The 
other continuous or ordinal variables were dichotomized ac-
cording to their median values. Univariate and multivariate 
multinomial logistic regression analysis was used for stroke 
severity (NIHSS score with the first tertile as the reference 
group). Univariate and multivariate binary logistic regression 
analyses were also performed to determine the predictive fac-
tors for functional outcome. Functional outcome was dichoto-
mized into good (mRS score of <3) or poor (mRS score of 
≥3). The cutoff for statistical significance was set at p<0.05 
(two-tailed).
Results
The demographic data of study subjects are given in Supple-
mentary Table 1 (in the online-only Data Supplement). The 
patients were aged 62±11 years, and 64.9% (161/248) were 
male. The LDL particle size was 25.9± 0.9 nm and the median 
NIHSS score was 3 (IQR=2–5). A history of diabetes mellitus, 
hemoglobin A1C and fasting glucose stroke was more fre-
quent or elevated in the ≥50% stenosis group than in the no-
atherosclerosis group. Smoking was more frequent in the no-
atherosclerosis and ≥50% stenosis groups than in the <50% 
stenosis group. Twenty-one patients had taken lipid-lowering 
agents prior to the index stroke (a statin only in 19 patients, 
and a statin and fenofibrate in 2). The LDL particles were 
smaller in the ≥50% stenosis group (24.5±0.8 nm) than in 
the no-atherosclerosis (25.9±0.8 nm) and <50% stenosis 
(25.2±0.7 nm) groups (Supplementary Table 1).
Association between clinical variables and LDL 
particle size
LDL particle size was inversely correlated with age (r=-0.171, 
p=0.013), serum TG concentration (r=-0.155, p=0.024), TG/
HDL ratio (r=-0.139, p=0.044), high-sensitivity C-reactive 
protein [high-sensitivity C-reactive protein (hs-CRP; r=-0.139, 
p=0.044)], NIHSS score (r=-0.228, p=0.012), and mRS score 
(r=-0.190, p=0.005). Furthermore, LDL particle size had mar-
ginally significant negative associations with hemoglobin (r= 
-0.118, p=0.086), white blood cell count (r=-0.122, p=0.077), 
hemoglobin A1C (r=-0.115, p=0.095), and fasting glucose 
level (r=-0.122, p=0.075). There was no statistically significant 
correlation between LDL particle size and any of the other 
variables.
Association between LDL particle size and 
stroke outcomes (severity and functional  
outcome at 3 months)
The relationship between LDL particle size and initial stroke 
severity was investigated after trichotomizing NIHSS scores. 
The LDL particles were smaller in the third tertile (NIHSS 
score ≥5) than in the second (NIHSS score 3 or 4) and first 
(NIHSS score 0–2) tertiles (24.8±0.7, 25.7±0.8, and 26.1±0.8 
nm, respectively; p=0.004) (Table 1). Moreover, 194 (78.2%) 
of the 248 patients had a good functional outcome, and the 
LDL particle size in these patients was 26.1±0.8 nm. The LDL 
particles were smaller (25.5±0.7 nm, p=0.003) in the remain-
ing 54 (21.8%) patients with a poor outcome than in patients 
with a good functional outcome (Table 2).
Regarding stroke severity, after adjusting for factors includ-
ing age, sex, and variables with p<0.1 in univariate analysis 
(white blood cell count, total cholesterol, LDL cholesterol, hs-
Song TJ et al.
www.thejcn.com  83
CRP, and fasting glucose), LDL particle size was indepen-
dently and inversely associated with stroke severity [NIHSS 
score ≥5, reference NIHSS score 0–2; odds ratio (OR)=0.38, 
p=0.028] (Table 3). Furthermore, LDL particle size was inde-
pendently and inversely associated with poor functional out-
come at discharge (mRS score ≥3; OR=0.44, p=0.038) after 
adjusting for age, sex, and variables with p<0.1 in univariate 
analysis (hemoglobin, hs-CRP, fasting glucose, degree of cere-
bral arterial stenosis, and NIHSS score) (Table 4).
Discussion
The findings of this study show that small LDL particles were 
associated with stroke severity and poor functional outcome in 
the studied patients, even after adjusting for NIHSS score, 
which is a strong predictive factor for stroke outcome. There 
are a few previous reports on this relationship. One study of 
200 patients with acute ischemic stroke found that small LDL 
particles were significantly associated with in-hospital mortal-
ity.14 Furthermore, in patients with coronary artery disease, 
and especially in those with acute myocardial infarction, the 
Table 1. Comparison of the demographic and clinical data according to stroke severity 
Characteristic
Stroke severity (NIHSS score)
p
0–2 (n=144) 3 or 4 (n=81) ≥5 (n=23)
Demographic data
Gender, male 98 (68.1) 49 (60.5) 14 (60.9) 0.476
Age (years)   61±12   63±12   65±10 0.070
Risk factors
Hypertension 62 (43.1) 31 (38.3)   9 (39.1) 0.767
Diabetes mellitus 50 (34.7) 21 (25.9)   6 (26.1) 0.339
Hyperlipidemia 18 (13.2) 17 (21.0) 2 (8.7) 0.194
Smoking 27 (18.8) 15 (18.5)   6 (26.1) 0.691
Familial history 6 (4.2) 3 (3.7) 2 (8.7) 0.574
Coronary heart disease 15 (10.4) 12 (14.8)   6 (26.1) 0.108
Medications
Prestroke lipid-lowering agents 12 (8.3) 8 (9.9) 1 (4.3) 0.700
Laboratory data
LDL particle size (nm) 26.1±0.8 25.7±0.8 24.8±0.7 0.004
Hemoglobin (g/L) 13±1 13±2 12±2 0.234
White blood cell count (×1012/L)   7±2   7±2   9±7 0.017
Total cholesterol (mg/dL) 179±34 187±31 169±40 0.041
HDL (mg/dL)   44±11   44±13   44±12 0.813
LDL (mg/dL) 111±32 122±28 100±34 0.013
Lipoprotein (a) (mg/dL)   23±21   23±20   18±11 0.438
TG (mg/dL) 124±64 107±56 122±82 0.282
Hemoglobin A1C (%)   6±1   6±1   7±2 0.285
hs-CRP   1±1   1±3   1±2 0.061
Fasting glucose (mg/dL) 104±33 109±43 127±57 0.031
TG/HDL ratio   3±2   3±2   3±4 0.443
Total cholesterol/HDL ratio   4±1   4±1   4±1 0.164
LDL/HDL ratio   2±0   2±1   2±1 0.014
Clinical data
Relevant cerebral artery stenosis 0.524
No atherosclerosis* 79 (54.9) 48 (59.3)   9 (39.1)
<50% stenosis† 35 (24.3) 19 (23.5)   7 (30.4)
≥50% stenosis‡ 30 (20.8) 14 (17.3)   7 (30.4)
Body mass index 23±2 23±2 23±2 0.203
The data are presented as n (%) or mean±SD values.
*No stenosis, †One or more vessels with <50% stenosis, ‡One or more vessels with 50% stenosis.
HDL: high-density lipoprotein, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, NIHSS: National Institutes of 
Health Stroke Scale, TG: triglycerides.
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LDL particles were reportedly relatively small, and this ten-
dency persisted during hospitalization.11 Consistent with this 
previous study in patients with acute myocardial infarction, 
the LDL particle size measured in the present study is also 
likely to have been affected by the acute-phase reaction of the 
lipolysis during acute ischemic stroke.
In addition, we found that small LDL particles were corre-
lated with atherogenic molecules such as TG and hs-CRP. 
These data are relatively consistent with the results of a study 
that evaluated carotid artery stenosis using a hospital-based, 
cross-sectional design22 and of a study that measured the rela-
tive LDL particle sizes in patients with metabolic syndrome, 
insulin resistance, or coronary heart disease.3 Since both serum 
TG and hs-CRP are closely associated with atherosclerosis via 
the inflammatory pathway,1 the present findings suggest that 
small LDL particles play an important role in atherogenicity 
or the inflammatory reaction in atherosclerosis.
The presence of an association between LDL particle size 
and stroke severity and poor functional outcomes may be at-
tributable to the following pleiotropic roles of small LDL par-
Table 2. Comparison of clinical variables between patients with a good and poor functional outcomes at 3 months
Characteristic
Functional outcome (mRS score)
p
0–2 (n=194) 3–6 (n=54)
Demographic data
Gender, male 130 (67.0) 31 (57.4) 0.191
Age (years)   61±12   64±11 0.152
Risk factors
Hypertension   80 (41.2) 22 (40.7) 0.948
Diabetes mellitus   60 (30.9) 17 (31.5) 0.938
Hyperlipidemia   29 (14.9)   9 (16.7) 0.757
Smoking   40 (20.6)   8 (14.8) 0.340
Familial history   7 (3.6) 4 (7.4) 0.230
Coronary heart disease   23 (11.9) 10 (18.5) 0.202
Medications
Prestroke lipid-lowering agents 19 (9.8) 2 (3.7) 0.155
Laboratory data
LDL particle size (nm) 26.1±0.8 25.5±0.7 0.003
Hemoglobin (g/L) 13±1 12±2 0.013
White blood cell count (×1012/L)   7±2   7±4 0.279
Total cholesterol (mg/dL) 179±34 187±31 0.761
HDL (mg/dL)   44±11   45±13 0.539
LDL (mg/dL) 113±32 115±30 0.750
Lipoprotein (a) (mg/dL)   22±19   25±23 0.421
TG (mg/dL) 119±64 114±63 0.613
Hemoglobin A1C (%)   6±1   7±2 0.074
hs-CRP   0±2   2±3 0.004
Fasting glucose (mg/dL) 105±37 119±46 0.048
TG/HDL ratio   3±2   3±2 0.856
Total cholesterol/HDL ratio   4±1   4±1 0.781
LDL/HDL ratio   2±1   2±1 0.930
Clinical data
Relevant cerebral artery stenosis 0.003
No atherosclerosis* 116 (59.8) 20 (37.0)
<50%†   46 (23.7) 15 (27.8)
≥50% stenosis‡   32 (16.5) 19 (35.2)
Body mass index 23±2 24±2 0.343
NIHSS [median (interquartile range)] 1 [0–2] 3 [3–4] 0.001
The data are presented as n (%), mean±SD values or median (interquatile ranges).
*No stenosis, †One or more vessels with <50% stenosis, ‡One or more vessels with 50% stenosis.
HDL: high-density lipoprotein, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, mRS: modified Rankin Scale, TG: 
triglycerides.
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ticles. First, small LDL particles are more atherogenic than 
their larger counterparts.22 It is known that small LDL particles 
are more easily taken up by arterial tissue, suggesting greater 
transendothelial transport, and they exhibit increased binding 
with polyanionic proteoglycans, which play a deterministic 
role in atherosclerosis.2 Since progressive cerebral atheroscle-
rosis is associated with a poor stroke outcome,23 the present 
results regarding the association between small LDL particles 
and stroke prognosis may be valid. Second, small LDL parti-
cles have a lower affinity for LDL receptors than do larger 
LDL particles.24 The lower affinity of small LDL particles for 
LDL receptors was reported to result in a longer retention time 
and consequently increased susceptibility to oxidative modifi-
cations.25 This altered balance in the antioxidant/oxidant mech-
anism may cause increased vascular thrombogenesis as well 
as severe atherogenesis.26 Moreover, increased thrombogene-
sis may contribute to atherothrombosis and poor stroke out-
come. Finally, small LDL particles are involved in the inflam-
matory cytokine signaling pathways. The excess infiltration in 
the arterial intima and local enzymatic modification of small 
LDL particles may trigger the expression of inflammatory cy-
tokines and vascular cell adhesion molecules. These cascades 
could ultimately lead to the formation of destabilizing lipid-
dominant cores and rupture prone fibrous caps on plaque.27 
This vulnerable atherosclerotic plaque is an important deter-
minant for thrombosis-related stroke with poor outcome, thus 
explaining the present finding of a relationship between stroke 
outcome and LDL particle size. Small LDL particles have also 
been reported to be inversely correlated with tumor necrosis 
factor α and interleukin-1β.28 These inflammatory cytokines 
are associated with activation of nuclear factor-κB, which is 
triggered by hypoxia, reactive oxygen species, and several in-
flammatory mediators, and is responsible for neuronal cell 
death and neurovascular unit injuries.29 Therefore, the pres-
ence of small LDL particles could reflect the severity or out-
come of ischemic brain injury.
This study was subject to some limitations. Blood samples 
were not drawn from a sample of the normal population for 
comparison. However, the objective of this study was to deter-
mine the relationship between LDL particle size and prognosis 
in stroke patients. Furthermore, such a comparative study be-
tween normal controls and stroke patients has already been 
performed,14 and it was found that LDL particles were smaller 
in stroke patients. Another limitation of the present study is 
that blood samples were obtained from acute stroke patients at 
admission, and LDL particle size was not serially assessed 
during the stroke time course. However, the patients’ lipid and 
lipoprotein levels remained stable during the 4-week follow-
up.30
In conclusion, small LDL particles are associated with ini-
tial stroke severity and are an independent predictor of poor 
functional outcome. Therefore, LDL particle size is a poten-
tial biomarker for the prognosis of atherothrombotic stroke.
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Table 3. Multinomial multivariate logistic regression regarding the 
association between LDL particle size and stroke severity (NIHSS 
score)†
Stroke severity (NIHSS score)
3 or 4 ≥5
Unadjusted model 0.69 (0.38–1.24) 0.36 (0.19–0.70)*
Adjusted model‡§ 0.69 (0.38–1.27) 0.33 (0.17–0.65)*
Adjusted model‡ǁ 0.72 (0.38–1.35) 0.31 (0.15–0.63)*
Adjusted model‡¶ 0.76 (0.40–1.44) 0.38 (0.19–0.78)*
*Statistically significant at p<0.05, †Reference NIHSS score, 0–2, 
‡Entered variables, §Age, sex, and LDL particle size, ǁAge, sex, 
and variables regarding lipid profile [LDL particle size, total 
cholesterol, HDL, LDL cholesterol, lipoprotein (a), and TG], 
¶Age, sex, and variables with p<0.1 in univariate analysis (LDL 
particle size, white blood cell count, total cholesterol, LDL cho-
lesterol, hs-CRP, and fasting glucose). 
HDL: high-density lipoprotein, hs-CRP: high-sensitivity C-reac-
tive protein, LDL: low-density lipoprotein, NIHSS: National Insti-
tutes of Health Stroke Scale, TG: triglycerides.
Table 4. Multivariate binary logistic regression regarding the de-
terminant factors associated with poor functional outcome
Characteristic OR (95% CI) p
Age 2.31 (0.82–6.50) 0.112
Sex 1.14 (0.41–3.18) 0.798
LDL particle size 0.44 (0.20–0.95) 0.038
Hemoglobin 2.22 (0.76–6.40) 0.140
hs-CRP 1.70 (0.63–4.58) 0.291
Fasting glucose 0.90 (0.34–2.41) 0.845
Degree of cerebral arterial  
  stenosis*
<50%   3.85 (1.12–13.26) 0.032
≥50% stenosis 16.78 (4.28–65.71) 0.001
NIHSS score†
3 or 4   4.69 (0.83–26.51) 0.080
≥5   21.29 (3.48–130.01) 0.001
*Reference: no relevant artery atherosclerosis, †Reference: NI-
HSS score, 0–2.
hs-CRP: high-sensitivity C-reactive protein, LDL: low-density li-
poprotein, NIHSS: National Institutes of Health Stroke Scale, OR: 
odds ratio, 95% CI: 95% confidence interval.
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Supplementary Table 1. Comparison of demographic and clinical data according to degree of cerebral artery stenosis 
Characteristics
Degree of stenosis
Total p valueNo atherosclerosis,
n=136
0<stenosis<50%,
n=61
≥50% stenosis,
n=51
Demographic data
Gender, male, n (%) 92 (67.6) 37 (60.7) 32 (62.7) 161 (64.9) 0.595
Age, years, mean±SD   61±11   63±14   63±10   62±11 0.405
Risk factors, n (%)
Hypertension 56 (41.2) 20 (32.8) 26 (51.0) 102 (41.1) 0.150
Diabetes mellitus 40 (29.4) 14 (23.0) 23 (45.1)   77 (31.0) 0.034
Hyperlipidemia 20 (14.7)   7 (11.5) 11 (21.6)   38 (15.3) 0.322
Smoking 32 (23.5) 5 (8.2) 11 (21.6)   48 (19.4) 0.038
Familial history 3 (2.2) 4 (6.6) 4 (7.8) 11 (4.4) 0.162
Coronary heart disease 13 (9.6) 10 (16.4) 10 (19.6)   33 (13.3) 0.141
Medications, n (%)
Pre-stroke lipid lowering agents 15 (11.0) 4 (6.6) 2 (3.9) 21 (8.5) 0.247
Laboratory data, mean±SD
LDL particle size, nm 25.9±0.8 25.2±0.7 24.5±0.8 25.9±0.9 0.010
Hemoglobin, g/L 13±2 13±1 12±2 13±2 0.098
White blood cell count, ×1012/L   6±2   7±2   8±4   7±3 0.104
Total cholesterol, mg/dL 177±34 189±28 181±37 181±34 0.085
High density lipoprotein, mg/dL   44±11   46±13   42±11   44±12 0.375
Low density lipoprotein, mg/dL 110±33 119±29 117±31 114±31 0.142
Lipoprotein (a), mg/dL   21±18  22 ±17   29±24   23±20 0.098
Triglyceride, mg/dL 116±67 120±59 122±62 118±64 0.497
Hemoglobin A1C, %   6±1   6±1   7±2   7±1 0.003
High sensitivity C-reactive protein   1±2   1±2   1±3   1±2 0.123
Fasting glucose, mg/dL 104±32 101±39 126±51 108±39 0.009
TG/HDL ratio   2±2   3±2   3±2   3±2 0.432
Total cholesterol/HDL ratio   4±1   4±1   4±2   4±1 0.325
LDL/HDL ratio   2±1   2±1   3±1   3±1 0.108
Clinical data
Body mass index, mean±SD 24±2 23±2 23±2 24±1 0.025
Initial NIHSS score, median  
  (interquartile range)
3 (1–5) 3 (1–5) 3 (2–5) 3 (2–5) 0.782
mRS score at 3 month, median  
  (interquartile range)
3 (1–5) 3 (1–5) 3 (2–5) 3 (2–5) 0.003
The data are presented as n (%), mean±SD values or median (interquatile ranges).
HDL: high-density lipoprotein, LDL: low-density lipoprotein, mRS: modified Rankin scale, NIHSS: National Institute of Health Stroke Scale, 
n: number, SD: standard deviation, TG: triglyceride.
